Previous 10 | Next 10 |
2023-05-09 18:04:59 ET Olema Pharmaceuticals press release ( NASDAQ: OLMA ): Q1 GAAP EPS of -$0.70 misses by $0.04 . Cash, cash equivalents and marketable securities as of March 31, 2023, were $186.0 million. Olema anticipates that this balance will be suffic...
Initiation of first pivotal Phase 3 monotherapy clinical trial of OP-1250 in second- and third-line metastatic breast cancer planned for the second half of 2023 Interim Phase 2 clinical results of OP-1250 in combination with palbociclib to be presented at the 2023 ESMO Breast Cancer Annua...
SAN FRANCISCO, May 08, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s ...
2023-04-21 17:40:45 ET Gainers: Starbucks Corporation ( SBUX ) +6% . Caesars Entertainment ( CZR ) +5% . Gritstone bio ( GRTS ) +4% . JFrog ( FROG ) +3% . UP Fintech Holding ( TIGR ) +3% . Losers: Presto Automation ...
SAN FRANCISCO, April 13, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s...
2023-03-10 11:19:47 ET Olema Oncology ( NASDAQ: OLMA ) will let go of ~25% of its employees across research, early development, and general and administrative functions as part of a restructuring. The move is being done so the company can focus on late-stage development of...
2023-03-09 17:25:45 ET Olema Pharmaceuticals press release ( NASDAQ: OLMA ): Q4 GAAP EPS of -$0.65 in-line. Cash, cash equivalents and marketable securities as of December 31, 2022, were $204.4 million. Olema anticipates that this balance will be sufficient to fu...
Significant progress made advancing lead program, OP-1250, with more than 170 patients treated to date Initiating first pivotal Phase 3 monotherapy clinical trial of OP-1250 in second- and third-line metastatic breast cancer in the second half of 2023 Corporate restructuri...
SAN FRANCISCO, March 02, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s...
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s ...
News, Short Squeeze, Breakout and More Instantly...
Olema Pharmaceuticals Inc. Company Name:
OLMA Stock Symbol:
NASDAQ Market:
Olema Pharmaceuticals Inc. Website:
2024-06-13 17:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-04 15:30:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for OLMA on June 4, 2024 02:10PM ET. The previous analyst recommendation was Outperform. OLMA was trading at $14.4 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is one of today's top gainers. The company's shares have moved 17.73% on the day to $13.84. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's ...